Vir Biotechnology/$VIR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vir Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Ticker
$VIR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
408
ISIN
US92764N1028
Website
VIR Metrics
BasicAdvanced
$706M
-
-$4.22
1.23
-
Price and volume
Market cap
$706M
Beta
1.23
52-week high
$14.45
52-week low
$4.32
Average daily volume
1.3M
Financial strength
Current ratio
6.79
Quick ratio
5.839
Long term debt to equity
8.447
Total debt to equity
8.447
Profitability
EBITDA (TTM)
-570.61
Gross margin (TTM)
-2,162.53%
Net profit margin (TTM)
-2,769.04%
Operating margin (TTM)
-2,794.20%
Effective tax rate (TTM)
0.24%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-23.49%
Return on equity (TTM)
-44.59%
Valuation
Price to revenue (TTM)
33.508
Price to book
0.68
Price to tangible book (TTM)
0.69
Price to free cash flow (TTM)
-1.656
Free cash flow yield (TTM)
-60.39%
Free cash flow per share (TTM)
-308.59%
Growth
Revenue change (TTM)
-73.79%
Earnings per share change (TTM)
5.22%
3-year revenue growth (CAGR)
-79.22%
3-year earnings per share growth (CAGR)
-22.27%
What the Analysts think about VIR
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
Bulls say / Bears say
Vir Biotechnology's strong financial position, with over $1 billion in cash and investments projected to fund operations into mid-2027, provides a solid foundation for ongoing research and development initiatives. (stocktitan.net)
The company's recent licensing agreement with Sanofi grants exclusive rights to three clinical-stage T-cell engagers, potentially enhancing its oncology pipeline and market competitiveness. (finance.yahoo.com)
Analysts have expressed optimism, with Barclays raising its price target for Vir Biotechnology to $31.00, indicating confidence in the company's growth prospects. (nasdaq.com)
Vir Biotechnology's decision not to proceed with Phase 3 development of its hepatitis B treatments without a global partner may delay potential revenue streams and impact investor confidence. (stocktitan.net)
The recent dismissal of all members of the CDC's Advisory Committee on Immunization Practices by U.S. Health Secretary Robert F. Kennedy Jr. introduces regulatory uncertainty that could affect vaccine development timelines. (reuters.com)
Despite a robust pipeline, Vir Biotechnology reported a net loss of $121.0 million in Q1 2025, reflecting ongoing financial challenges in achieving profitability. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
VIR Financial Performance
Revenues and expenses
VIR Earnings Performance
Company profitability
VIR News
AllArticlesVideos
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
Business Wire·1 month ago
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Business Wire·2 months ago
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vir Biotechnology stock?
Vir Biotechnology (VIR) has a market cap of $706M as of July 02, 2025.
What is the P/E ratio for Vir Biotechnology stock?
The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of July 02, 2025.
Does Vir Biotechnology stock pay dividends?
No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of July 02, 2025.
When is the next Vir Biotechnology dividend payment date?
Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vir Biotechnology?
Vir Biotechnology (VIR) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.